The study analyzed 365 cases of metastatic bone tumors over two decades, focusing on clinical features and primary cancer sites in cases of unknown origin.
The spine was found to be the most commonly affected area, and metastatic disease was the initial presentation for 69.5% of patients, with the primary cancer identified in only 220 cases.
Immunohistochemistry (IHC) helped determine the likely origin of tumors in nearly 27.4% of patients with unknown primary sites, highlighting the significance of thorough testing for effective treatment strategies.